Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANHYDRON vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,Hypertension (off-label use)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Partially metabolized by the liver; primarily excreted unchanged in urine.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
95% bound, primarily to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~65% (range 50-80%) due to first-pass metabolism.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 10-50 m L/min: 50 mg every 12 hours. GFR <10 m L/min: 50 mg every 24 hours or not recommended.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
1-2 mg/kg/dose once daily; maximum 100 mg/day.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at 12.5-25 mg once daily; titrate slowly due to risk of hypotension and electrolyte imbalance.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No FDA black box warning.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Electrolyte imbalance (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypotension,Ototoxicity (especially with rapid IV administration or renal impairment),Hyperuricemia and gout,Sulfonamide cross-sensitivity in sulfa-allergic patients
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Anuria,Severe renal failure,Hepatic coma or pre-coma,Severe electrolyte depletion,Hypersensitivity to sulfonamides
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) as hyperkalemia may occur. Limit salt substitutes containing potassium. Grapefruit juice may increase drug absorption; avoid concurrent use. Alcohol may enhance orthostatic hypotension.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been associated with an increased risk of congenital anomalies in some studies, including cleft lip/palate and cardiac defects. Second and third trimesters: can cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly intrauterine growth restriction. Crosses the placenta. Use only if clearly needed for maternal conditions like hypertension or edema.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Cyclothiazide is excreted into human breast milk. The milk-to-plasma ratio is not well defined for cyclothiazide but for thiazides generally is around 0.5-1.0. May suppress lactation. Potential for infant adverse effects (e.g., electrolyte disturbances, thrombocytopenia). Use caution in breastfeeding; alternatives are preferred.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal blood flow, and GFR) may reduce effectiveness of thiazides. No specific dosing adjustment guidelines for cyclothiazide; however, if used, start at lowest effective dose and titrate based on response. Typical adult dose: 2 mg once daily; may adjust to 1-4 mg. Monitor for hypotension and electrolyte imbalances. Avoid in preeclampsia due to decreased placental perfusion.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
ANHYDRON (cyclothiazide) is a thiazide-like diuretic used for hypertension and edema. Monitor serum potassium and glucose levels; hypokalemia and hyperglycemia are common. Use with caution in renal impairment (Cr Cl <30 m L/min). Avoid in patients with anuria or sulfonamide allergy.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Do not stop abruptly without consulting your doctor; gradual dose reduction may be needed.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANHYDRON vs ABSTRAL, answered by our medical review team.
ANHYDRON is a Thiazide Diuretic that works by Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANHYDRON and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANHYDRON is: Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANHYDRON and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANHYDRON is classified as Category C. Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been asso. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.